SI2540309T1 - Tkivni zaščitni peptidi in njihove uporabe - Google Patents
Tkivni zaščitni peptidi in njihove uporabe Download PDFInfo
- Publication number
- SI2540309T1 SI2540309T1 SI200632233T SI200632233T SI2540309T1 SI 2540309 T1 SI2540309 T1 SI 2540309T1 SI 200632233 T SI200632233 T SI 200632233T SI 200632233 T SI200632233 T SI 200632233T SI 2540309 T1 SI2540309 T1 SI 2540309T1
- Authority
- SI
- Slovenia
- Prior art keywords
- amino acid
- disease
- isolated polypeptide
- cell
- protective activity
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 31
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 24
- 230000002669 organ and tissue protective effect Effects 0.000 title claims 2
- 229920001184 polypeptide Polymers 0.000 claims abstract 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 13
- 201000010099 disease Diseases 0.000 claims abstract 8
- 208000035475 disorder Diseases 0.000 claims abstract 5
- 238000006467 substitution reaction Methods 0.000 claims abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 4
- 210000003169 central nervous system Anatomy 0.000 claims abstract 3
- 230000006378 damage Effects 0.000 claims abstract 3
- 208000014674 injury Diseases 0.000 claims abstract 3
- 210000001428 peripheral nervous system Anatomy 0.000 claims abstract 3
- 208000027418 Wounds and injury Diseases 0.000 claims abstract 2
- 238000011321 prophylaxis Methods 0.000 claims abstract 2
- 230000001225 therapeutic effect Effects 0.000 claims abstract 2
- 238000011282 treatment Methods 0.000 claims abstract 2
- 150000001413 amino acids Chemical group 0.000 claims 10
- 230000001681 protective effect Effects 0.000 claims 9
- 230000001413 cellular effect Effects 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 238000010171 animal model Methods 0.000 claims 2
- 230000003833 cell viability Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 210000004295 hippocampal neuron Anatomy 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 210000002569 neuron Anatomy 0.000 claims 2
- 230000004112 neuroprotection Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 230000004224 protection Effects 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 230000004888 barrier function Effects 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 210000001759 blood-nerve barrier Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 201000006306 Cor pulmonale Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 208000021642 Muscular disease Diseases 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 238000007792 addition Methods 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 208000010643 digestive system disease Diseases 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 230000006371 metabolic abnormality Effects 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000004994 reproductive system Anatomy 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
Claims (19)
- Tkivni zaščitni peptidi in njihove uporabe PATENTNI ZAHTEVKI1. Izoliran polipeptid, ki ga sestavlja največ 15 aminokislinskih ostankov in vsebuje aminokislinsko sekvenco WEHVNAIQEARRLL (SEQ ID NO: 35), kjer ima omenjeni polipeptid celično zaščitno aktivnost, pri čemer je celična zaščitna aktivnost določena in vivo v živalskem modelu zaščite pred poškodbami na ishiadičnem živcu ali kjer celična zaščitna aktivnost obsega neuroprotekcijo, ki se in vitro določi z metodo, ki obsega korake: (a) kontaktiranje testne kulture primarnih hipokampalnih nevronov z N-metil-D-aspartatom in navedenim peptidom; in (b) določanje celične viabilnosti 48 ur po omenjenem stiku, tako da če je celična vialbilnost določena v koraku (b) večja od tiste kontrolne kulture v odsotnosti navedenega peptida, ima peptid celično zaščitno aktivnost.
- 2. Izoliran polipeptid, ki sestoji iz aminokislinskega zaporedja WEHVNAIQEARRLL (SEQ ID NO: 35).
- 3. Izoliran polipeptid, ki sestoji iz aminokislinskega zaporedja WEHVNAIQEARRLL (SEQ ID NO: 35), pri čemer se en aminokislinski ostanek omenjene aminokislinske sekvence nadomesti s konzervativno ali ne- konzervativno aminokislinsko substitucijo ali aminokislinskim ekvivalentom, ki ima modifikacijo stranske verige ali substitucijo stranske verige, kjer ima omenjeni polipeptid celično zaščitno aktivnost, pri čemer se celična zaščitna aktivnost določi in vivo v živalskem modelu zaščite pred poškodbami na ishiadičnem živcu ali kjer celična zaščitna aktivnost obsega neuroprotekcijo, ki se in vitro določi z metodo, ki obsega korake: (a) kontaktiranje testne kulture primarnih hipokampalnih nevronov z N-metil-D-aspartatom in navedenim peptidom; in (b) določanje celične viabilnosti 48 ur po omenjenem stiku, tako da če je celična vialbilnost določena v koraku (b) večja od tiste kontrolne kulture v odsotnosti navedenega peptida, ima peptid celično zaščitno aktivnost.
- 4. Izolirani polipeptid po zahtevku 3, kjer je omenjeni en aminokislinski ostanek aminokislinskega zaporedja zamenjan s konzervativno ali ne-konzervativno aminokislinsko substitucijo.
- 5. Izolirani polipeptid po zahtevku 3, kjer je omenjeni en aminokislinski ostanek aminokislinskega zaporedja zamenjan z aminokislinskim ekvivalentom, ki ima modifikacijo stranske verige ali substitucijo stranske verige.
- 6. Izoliran polipeptid, ki je izolirani polipeptid po katerem koli od zahtevkov 1-5, modificiran z dodatkom polietilen glikola.
- 7. Izolirani polipeptid po katerem koli od zahtevkov 1-6, kjer je celična zaščitna aktivnost v vzdraženem tkivu iz skupine, ki jo sestavljajo tkivo osrednjega živčnega sistema in tkivo perifernega živčnega sistema.
- 8. Izolirani polipeptid po katerem koli od zahtevkov 1-6, kjer je omenjeni polipeptid sposoben prestopati endotelno celično bariero, izbrano iz skupine, ki jo sestavljajo krvno-možganska pregrada, kri-oko pregrada, kri-moda pregrada, kri-ovariji pregrada, kri-živci pregrada in kri-hrbetnjača pregrada.
- 9. Farmacevtski sestavek, ki obsega izolirani polipeptid po katerem koli od zahtevkov 1-8 in farmacevtsko sprejemljiv nosilec.
- 10. Farmacevtski sestavek po zahtevku 9, kjer je omenjeni sestavek formuliran za oralno, intranazalno, inhalacijsko, transdermalno, rektalno, sublingvalno ali parenteralno dajanje, ali kjer je sestavek formuliran kot perfuzatna raztopina.
- 11. Metoda za zaščito, vzdrževanje ali izboljšanje viabilnosti nevronske celice, tkiva ali organa, izoliranega iz telesa sesalcev, ki obsega izpostavitev omenjene nevronske celice, tkiva ali organa in vitro izoliranemu polipeptidu po katerem koli od zahtevkov 1-8 ali farmacevtskemu sestavku po katerem koli od zahtevkov 9-10.
- 12. Metoda po zahtevku 11, kjer je telo sesalcev človeško telo.
- 13. Izoliran polipeptid po katerem koli od zahtevkov 1-8 za uporabo pri metodi preprečevanja, terapevtskega zdravljenja ali profilaktičnega zdravljenja bolezni ali motnje osrednjega ali perifernega živčnega sistema pri pri subjektu, ki le to potrebuje.
- 14. Izolirani polipeptid za uporabo po zahtevku 13, kjer je subjekt človek.
- 15. Izolirana nukleinska kislina, ki obsega nukleotidno sekvenco, ki kodira izolirani polipeptid po katerem koli od zahtevkov 1-8.
- 16. Vektor, ki obsega nukleinsko kislino po zahtevku 15.
- 17. Vektor po zahtevku 16, kjer je vektor ekspresijski vektor.
- 18. Gostiteljska celica, ki vsebuje ekspresijski vektor po zahtevku 17.
- 19. Metoda za rekombinantno proizvodnjo izoliranega polipeptida, ki obsega (a) kultiviranje v mediju gostiteljske celice po zahtevku 18, pod pogoji, primernimi za izražanje omenjenega polipeptida, in (b) rekuperiranje in izoliranje navedenega polipeptida iz navedenega medija.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70574105P | 2005-08-05 | 2005-08-05 | |
US70627605P | 2005-08-08 | 2005-08-08 | |
US83173706P | 2006-07-18 | 2006-07-18 | |
EP12175352.9A EP2540309B1 (en) | 2005-08-05 | 2006-08-07 | Tissue protective peptides and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2540309T1 true SI2540309T1 (sl) | 2018-04-30 |
Family
ID=37728020
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200631979T SI2371855T1 (sl) | 2005-08-05 | 2006-08-07 | Peptidi, ki ščitijo tkiva, in načini njihove uporabe |
SI200632230T SI2594279T1 (sl) | 2005-08-05 | 2006-08-07 | Tkivni zaščitni peptidi in njihove uporabe |
SI200632233T SI2540309T1 (sl) | 2005-08-05 | 2006-08-07 | Tkivni zaščitni peptidi in njihove uporabe |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200631979T SI2371855T1 (sl) | 2005-08-05 | 2006-08-07 | Peptidi, ki ščitijo tkiva, in načini njihove uporabe |
SI200632230T SI2594279T1 (sl) | 2005-08-05 | 2006-08-07 | Tkivni zaščitni peptidi in njihove uporabe |
Country Status (26)
Country | Link |
---|---|
US (7) | US8071554B2 (sl) |
EP (5) | EP3363451A1 (sl) |
JP (6) | JP5274253B2 (sl) |
KR (7) | KR20180116475A (sl) |
CN (2) | CN101378772B (sl) |
AU (1) | AU2006278264B2 (sl) |
BR (1) | BRPI0614529A8 (sl) |
CA (3) | CA2618396C (sl) |
DK (3) | DK2540309T3 (sl) |
EA (1) | EA015672B1 (sl) |
ES (3) | ES2550055T3 (sl) |
HK (1) | HK1127751A1 (sl) |
HU (3) | HUE035793T2 (sl) |
IL (3) | IL189287A (sl) |
IN (1) | IN2014CN02050A (sl) |
LT (2) | LT2594279T (sl) |
MX (3) | MX2008001509A (sl) |
NO (1) | NO20081112L (sl) |
NZ (1) | NZ565937A (sl) |
PL (3) | PL2594279T3 (sl) |
PT (3) | PT2540309T (sl) |
SG (2) | SG2014007868A (sl) |
SI (3) | SI2371855T1 (sl) |
UA (1) | UA100222C2 (sl) |
WO (1) | WO2007019545A2 (sl) |
ZA (1) | ZA201101890B (sl) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
US9345745B2 (en) * | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
WO2007052154A2 (en) * | 2005-04-29 | 2007-05-10 | University Of Medicine And Dentistry Of New Jersey | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
US9585932B2 (en) * | 2005-04-29 | 2017-03-07 | Peter C. Dowling | Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders |
HUE035793T2 (en) * | 2005-08-05 | 2018-05-28 | Araim Pharmaceuticals Inc | Cell protection peptides and their applications |
RU2008152746A (ru) * | 2006-06-07 | 2010-07-20 | Дзе Юниверсити Оф Токусима (Jp) | Лечение ишемических заболеваний с применением эритропоэтина |
EP2081956B1 (en) | 2006-11-13 | 2013-03-20 | Charité - Universitätsmedizin Berlin | Method of cell culture and method of treatment comprising a vepo protein variant |
AU2016203452B2 (en) * | 2008-01-22 | 2018-02-22 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
AU2014203195B2 (en) * | 2008-01-22 | 2016-03-31 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
KR20180041269A (ko) | 2008-01-22 | 2018-04-23 | 아라임 파마슈티칼즈, 인크. | 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체 |
WO2012051581A2 (en) * | 2010-10-14 | 2012-04-19 | Rutgers, The State University Of New Jersey | Intestinal peptide targeting ligands |
US9566349B2 (en) * | 2010-10-14 | 2017-02-14 | Rutgers, The State University Of New Jersey | Intestinal peptide targeting ligands |
CN102180948A (zh) * | 2011-03-03 | 2011-09-14 | 复旦大学附属中山医院 | 一种具有肾脏保护作用的短肽及其制备方法和应用 |
CN102212111B (zh) * | 2011-05-05 | 2014-04-30 | 中国人民解放军第三军医大学 | 小分子多肽和小分子多肽脂质体及其运用 |
WO2013016634A1 (en) * | 2011-07-27 | 2013-01-31 | Neumedicines, Inc. | Use of il-12 to generate endogenous erythropoietin |
US20140249573A1 (en) * | 2011-09-20 | 2014-09-04 | A.A. Cash Technology Ltd. | Methods and devices for occluding blood flow to an organ |
KR101148191B1 (ko) * | 2011-09-27 | 2012-05-23 | 김후정 | 에리스로포이에틴-유래 펩타이드 및 그 용도 |
WO2013158871A1 (en) | 2012-04-20 | 2013-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of erythropoietin and derivatives for treating hypertension |
CA2918223A1 (en) * | 2013-07-17 | 2015-01-22 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
CN104744593A (zh) * | 2013-12-25 | 2015-07-01 | 深圳先进技术研究院 | 一种抗肿瘤血管生成免疫复合肽及其制备方法和应用 |
US9622483B2 (en) | 2014-02-19 | 2017-04-18 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
US11039621B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
US11039620B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
KR20150130616A (ko) * | 2014-05-13 | 2015-11-24 | (주)케어젠 | 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도 |
CN105924505A (zh) * | 2014-06-22 | 2016-09-07 | 马恒标 | 组织保护活性多肽sl12及其应用 |
SG11201802777XA (en) * | 2015-10-14 | 2018-05-30 | X Therma Inc | Compositions and methods for reducing ice crystal formation |
US10864253B2 (en) | 2016-04-29 | 2020-12-15 | Araim Pharmaceuticals, Inc. | Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage |
PL3538065T3 (pl) | 2016-11-10 | 2023-12-04 | Asc Regenity Ltd. | Formulacje kosmetyczne do zastosowań miejscowych zawierające cząsteczki pochodzące z erytropoetyny |
EP3587443A4 (en) | 2017-02-27 | 2021-02-17 | Sylus Co., Ltd. | USE OF ERYTHROPOIETIN PEPTIDE BY EFFECT ON CELL DAMAGE PREVENTION THEREOF |
WO2018157773A1 (zh) | 2017-02-28 | 2018-09-07 | 暨南大学 | 一种促进创伤后组织修复与再生的修复肽及其应用 |
CN108503690B (zh) * | 2017-02-28 | 2020-07-03 | 暨南大学 | 一种促进创伤后组织修复与再生的修复肽及其应用 |
WO2019199661A1 (en) * | 2018-04-08 | 2019-10-17 | Brim Biotechnology, Inc. | Application of pedf-derived short peptides in tendon healing |
KR102300060B1 (ko) | 2018-06-12 | 2021-09-08 | 주식회사 엘지에너지솔루션 | 2열 터미널 구조의 pcb 다이렉트 커넥터 |
US20220049011A1 (en) | 2018-09-10 | 2022-02-17 | Cold Spring Harbor Laboratory | Methods for treating pancreatitis |
CN112390877B (zh) * | 2019-08-16 | 2022-10-04 | 董红燕 | Pedf衍生多肽组合物及其在制备保护肺损伤药物中的应用 |
CN118255845A (zh) * | 2022-12-27 | 2024-06-28 | 上海瑞吉康生物医药有限公司 | 相分离逆转多肽的变体及其应用 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
US4558006A (en) | 1983-02-04 | 1985-12-10 | Kirin-Amgen, Inc. | A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin |
US5051448A (en) | 1984-07-24 | 1991-09-24 | The Mclean Hospital Corporation | GABA esters and GABA analog esters |
US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
US4798824A (en) | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
US5498694A (en) | 1989-05-25 | 1996-03-12 | La Jolla Cancer Research Foundation | Peptides of the cytoplasmic domain of integrin |
DE3924746A1 (de) * | 1989-07-26 | 1991-01-31 | Behringwerke Ag | Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper |
WO1991004014A1 (en) | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
US6140120A (en) * | 1993-02-12 | 2000-10-31 | Board Of Trustees Of Leland Stanford Jr. University | Regulated transcription of targeted genes and other biological events |
US5559103A (en) | 1993-07-21 | 1996-09-24 | Cytel Corporation | Bivalent sialyl X saccharides |
US5700909A (en) * | 1993-07-30 | 1997-12-23 | The Regents Of The University Of California | Prosaposin and cytokine-derived peptides |
US5571787A (en) | 1993-07-30 | 1996-11-05 | Myelos Corporation | Prosaposin as a neurotrophic factor |
WO1995021919A2 (en) * | 1994-02-14 | 1995-08-17 | Kirin Brewery Company, Limited | Protein having tpo activity |
ITFI940106A1 (it) * | 1994-05-27 | 1995-11-27 | Menarini Ricerche Sud Spa | Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica |
US5576423A (en) | 1994-12-02 | 1996-11-19 | Schering Corporation | Antibodies to the slam protein expressed on activated T cells |
DE69630708T2 (de) * | 1995-06-07 | 2004-08-05 | Ortho Pharmaceutical Corp. | An den erythropoietin-rezeptor bindende zusammensetzungen und peptide |
AU4267297A (en) * | 1997-09-11 | 1998-09-22 | Regents Of The University Of California, The | Method of alleviating neuropathic pain |
US7270809B2 (en) * | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
US7153943B2 (en) * | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
NZ514690A (en) | 1999-04-13 | 2004-07-30 | Kenneth S | Modulation of excitable tissue function by peripherally administered erythropoietin |
WO2001083548A1 (fr) * | 2000-04-28 | 2001-11-08 | Effector Cell Institute | Nouveau derive de facteur chimiotactique cellulaire |
AU2002233230B2 (en) * | 2000-12-20 | 2007-02-01 | F. Hoffmann-La Roche Ag | Erythropoietin conjugates |
PA8536201A1 (es) | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
WO2002062843A2 (en) * | 2001-02-06 | 2002-08-15 | Merck Patent Gmbh | Modified erythropoietin (epo) with reduced immunogenicity |
CA2443373A1 (en) * | 2001-04-04 | 2002-10-31 | Genodyssee | New polynucleotides and polypeptides of the erythropoietin gene |
KR100467751B1 (ko) * | 2001-12-03 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
US7300915B2 (en) * | 2002-06-05 | 2007-11-27 | The Regents Of The University Of California | Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain |
EP1552298A4 (en) | 2002-07-01 | 2006-11-08 | Kenneth S Warren Inst Inc | RECOMBINANT TISSUE-PROOFING CYTOKINS AND NUCLEIC ACIDS COORDINATING THEREOF FOR THE PROTECTION, RECOVERY AND IMPROVEMENT OF CELLS, TISSUE AND ORGANS THEREOF |
KR100478455B1 (ko) | 2002-08-19 | 2005-03-22 | 삼성전자주식회사 | 전자렌지 |
AU2003273297A1 (en) | 2002-09-09 | 2004-03-29 | Kenneth S. Warren Institute, Inc. | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
CA2500715A1 (en) * | 2002-10-03 | 2004-04-15 | Epimmune, Inc. | Hla binding peptides and their uses |
JP2004305006A (ja) * | 2003-04-01 | 2004-11-04 | Japan Science & Technology Agency | 人工調製肺サーファクタント |
US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
US9617516B2 (en) * | 2003-04-25 | 2017-04-11 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Muscle-derived cells (MDCs) for promoting and enhancing nerve repair and regeneration |
CN1882355A (zh) | 2003-09-09 | 2006-12-20 | 沃伦药品公司 | 保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素 |
CA2539440A1 (en) | 2003-09-29 | 2005-04-14 | Warren Pharmaceuticals, Inc. | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions |
US7842661B2 (en) | 2003-11-24 | 2010-11-30 | Novo Nordisk A/S | Glycopegylated erythropoietin formulations |
US20080227696A1 (en) * | 2005-02-22 | 2008-09-18 | Biosurface Engineering Technologies, Inc. | Single branch heparin-binding growth factor analogs |
WO2007010552A2 (en) | 2005-03-17 | 2007-01-25 | Serum Institute Of India Limited | N- terminal peg conjugate of erythropoietin |
US9345745B2 (en) | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
WO2007052154A2 (en) | 2005-04-29 | 2007-05-10 | University Of Medicine And Dentistry Of New Jersey | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
US8329652B2 (en) | 2005-05-10 | 2012-12-11 | Neoloch Aps | Neuritogenic peptides |
EP1736481A1 (en) | 2005-05-13 | 2006-12-27 | Charite Universitätsmedizin-Berlin | Erythropoietin variants |
HUE035793T2 (en) | 2005-08-05 | 2018-05-28 | Araim Pharmaceuticals Inc | Cell protection peptides and their applications |
EP2109690B9 (en) | 2007-11-29 | 2012-10-24 | MOLECULAR HEALTH GmbH | Eph-b4 specific sirna for reducing epo-induced tumor cell growth during anemia treatment in cancer patients, tissue protective erythropoietin receptor (nepor) and methods of use. |
KR20180041269A (ko) | 2008-01-22 | 2018-04-23 | 아라임 파마슈티칼즈, 인크. | 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체 |
AU2009243187C1 (en) * | 2008-04-28 | 2015-12-24 | President And Fellows Of Harvard College | Supercharged proteins for cell penetration |
WO2011022056A2 (en) | 2009-08-18 | 2011-02-24 | Medical College Of Georgia Research Institute, Inc. | PEPTIDE MODULATORS OF THE δPKC INTERACTION WITH THE D SUBUNIT OF F1FO ATP SYNTHASE/ATPASE AND USES THEREOF |
-
2006
- 2006-08-07 HU HUE12175352A patent/HUE035793T2/en unknown
- 2006-08-07 SG SG2014007868A patent/SG2014007868A/en unknown
- 2006-08-07 ES ES11163194.1T patent/ES2550055T3/es active Active
- 2006-08-07 CA CA2618396A patent/CA2618396C/en not_active Expired - Fee Related
- 2006-08-07 SI SI200631979T patent/SI2371855T1/sl unknown
- 2006-08-07 JP JP2008525285A patent/JP5274253B2/ja not_active Expired - Fee Related
- 2006-08-07 WO PCT/US2006/031061 patent/WO2007019545A2/en active Application Filing
- 2006-08-07 DK DK12175352.9T patent/DK2540309T3/en active
- 2006-08-07 SI SI200632230T patent/SI2594279T1/sl unknown
- 2006-08-07 CA CA2982909A patent/CA2982909A1/en not_active Abandoned
- 2006-08-07 CA CA3079319A patent/CA3079319A1/en not_active Abandoned
- 2006-08-07 SG SG10201805825SA patent/SG10201805825SA/en unknown
- 2006-08-07 MX MX2008001509A patent/MX2008001509A/es active IP Right Grant
- 2006-08-07 EP EP17202352.5A patent/EP3363451A1/en not_active Withdrawn
- 2006-08-07 US US11/997,898 patent/US8071554B2/en not_active Expired - Fee Related
- 2006-08-07 NZ NZ565937A patent/NZ565937A/en not_active IP Right Cessation
- 2006-08-07 DK DK11163194.1T patent/DK2371855T3/en active
- 2006-08-07 CN CN2006800348244A patent/CN101378772B/zh not_active Expired - Fee Related
- 2006-08-07 IN IN2050CHN2014 patent/IN2014CN02050A/en unknown
- 2006-08-07 PT PT121753529T patent/PT2540309T/pt unknown
- 2006-08-07 PT PT121753669T patent/PT2594279T/pt unknown
- 2006-08-07 AU AU2006278264A patent/AU2006278264B2/en not_active Ceased
- 2006-08-07 PT PT111631941T patent/PT2371855E/pt unknown
- 2006-08-07 PL PL12175366T patent/PL2594279T3/pl unknown
- 2006-08-07 PL PL12175352T patent/PL2540309T3/pl unknown
- 2006-08-07 HU HUE12175366A patent/HUE035655T2/en unknown
- 2006-08-07 KR KR1020187030050A patent/KR20180116475A/ko not_active Application Discontinuation
- 2006-08-07 SI SI200632233T patent/SI2540309T1/sl unknown
- 2006-08-07 BR BRPI0614529A patent/BRPI0614529A8/pt not_active Application Discontinuation
- 2006-08-07 PL PL11163194T patent/PL2371855T3/pl unknown
- 2006-08-07 KR KR1020137016015A patent/KR101713368B1/ko active IP Right Grant
- 2006-08-07 KR KR1020087005373A patent/KR101626153B1/ko active IP Right Grant
- 2006-08-07 EA EA200800536A patent/EA015672B1/ru not_active IP Right Cessation
- 2006-08-07 CN CN201310529242.5A patent/CN103724418B/zh not_active Expired - Fee Related
- 2006-08-07 MX MX2016004825A patent/MX364100B/es unknown
- 2006-08-07 EP EP12175366.9A patent/EP2594279B1/en active Active
- 2006-08-07 DK DK12175366.9T patent/DK2594279T3/en active
- 2006-08-07 EP EP12175352.9A patent/EP2540309B1/en active Active
- 2006-08-07 EP EP11163194.1A patent/EP2371855B1/en active Active
- 2006-08-07 HU HUE11163194A patent/HUE026444T2/en unknown
- 2006-08-07 ES ES12175366.9T patent/ES2653790T3/es active Active
- 2006-08-07 LT LTEP12175366.9T patent/LT2594279T/lt unknown
- 2006-08-07 EP EP06801051A patent/EP1924276A4/en not_active Withdrawn
- 2006-08-07 KR KR1020187016750A patent/KR20180067735A/ko not_active Application Discontinuation
- 2006-08-07 KR KR1020197019568A patent/KR20190084136A/ko not_active Application Discontinuation
- 2006-08-07 KR KR1020177005579A patent/KR20170027868A/ko active Search and Examination
- 2006-08-07 ES ES12175352.9T patent/ES2653864T3/es active Active
- 2006-08-07 MX MX2014011168A patent/MX339613B/es unknown
- 2006-08-07 KR KR1020207016998A patent/KR20200072568A/ko not_active Application Discontinuation
- 2006-08-07 UA UAA200802850A patent/UA100222C2/uk unknown
- 2006-08-07 LT LTEP12175352.9T patent/LT2540309T/lt unknown
-
2008
- 2008-02-05 IL IL189287A patent/IL189287A/en active IP Right Grant
- 2008-03-03 NO NO20081112A patent/NO20081112L/no not_active Application Discontinuation
-
2009
- 2009-08-21 HK HK09107682.9A patent/HK1127751A1/xx not_active IP Right Cessation
-
2011
- 2011-03-11 ZA ZA2011/01890A patent/ZA201101890B/en unknown
- 2011-10-20 US US13/278,131 patent/US8716245B2/en not_active Expired - Fee Related
-
2012
- 2012-04-16 US US13/448,345 patent/US8673861B2/en not_active Expired - Fee Related
-
2013
- 2013-02-15 JP JP2013027479A patent/JP5918155B2/ja not_active Expired - Fee Related
-
2014
- 2014-04-08 US US14/248,030 patent/US9340598B2/en not_active Expired - Fee Related
-
2015
- 2015-02-04 JP JP2015020020A patent/JP6158235B2/ja not_active Expired - Fee Related
- 2015-02-10 US US14/618,873 patent/US20150152156A1/en not_active Abandoned
- 2015-06-29 IL IL239695A patent/IL239695A0/en active IP Right Grant
-
2016
- 2016-05-05 US US15/147,848 patent/US10100096B2/en not_active Expired - Fee Related
- 2016-06-08 JP JP2016114010A patent/JP6491621B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-03 JP JP2018071318A patent/JP2018134084A/ja active Pending
- 2018-08-23 IL IL261346A patent/IL261346A/en unknown
- 2018-09-25 US US16/141,724 patent/US20190016769A1/en not_active Abandoned
-
2020
- 2020-01-30 JP JP2020013151A patent/JP2020078317A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2540309T1 (sl) | Tkivni zaščitni peptidi in njihove uporabe | |
Abematsu et al. | Neurons derived from transplanted neural stem cells restore disrupted neuronal circuitry in a mouse model of spinal cord injury | |
DK2864360T3 (en) | TARGETED THERAPY | |
JP2009508471A5 (sl) | ||
ES2595103T3 (es) | Células Tr1, células madre mesenquimales y usos de estas | |
JP2013126995A5 (sl) | ||
NZ587105A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
US20130109626A1 (en) | Novel peptide and use thereof | |
AR059371A1 (es) | Terapia genica para la enfermedad de niemann-pick tipo a | |
KR20120051006A (ko) | 세포 요법에 사용하기 위한 방법 및 조성물 | |
ITMI942025A1 (it) | Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia | |
WO2010135491A3 (en) | Fibroblast growth factor mutants having improved functional half-life and methods of their use | |
JP2019513752A (ja) | 神経変性疾患を治療するためのtdp−43のミトコンドリア局在化阻害剤 | |
EP3583117B1 (en) | In vitro method for fusing two or more cells, in vitro, method for delivering a gene of interest, and pharmaceutical composition for use in the treatment of a disease | |
JP2009507474A5 (sl) | ||
WO2012088001A3 (en) | Antiviral activity of bovine type iii interferon against foot-and-mouth disease virus | |
EP3863655A1 (en) | Lactococcus lactis expression system for delivering proteins efficacious for the treatment of epithelial barrier function disorders | |
US20200277627A1 (en) | Rna replicon for reprogramming somatic cells | |
JP2004537274A5 (sl) | ||
ES2723098T3 (es) | Agonistas del péptido CRHR2 y usos de los mismos | |
EP3341739A1 (en) | Mutant peptides and methods of treating subjects using the same | |
CA2426381A1 (en) | Cell damage inhibitor | |
JP2019512216A5 (sl) | ||
Boheler | Pluripotency of human embryonic and induced pluripotent stem cells for cardiac and vascular regeneration | |
EP2918287B1 (en) | Pre-incubation of T cells |